Disulfide bond reduction of antibodies during clarification: A bench‐scale assay and a mitigation tool
Biotechnology Progress · 2026-07 · 42 (4)
DOI: 10.1002/btpr.88507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, online erschienen am 03.04.2026. Verfasst von Hendri Tjandra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biologics Pilot Lab, PDM, Gilead Sciences, Foster City, California, USA. Hauptthemen laut MEDLINE: Disulfides, Antibodies, Monoclonal, Antibodies. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We investigated side‐by‐side clarification with a two‐stage depth filter system against a single‐stage charge chromatographic clarifier on a number of Chinese hamster ovary (CHO) cell cultures. We found that the one‐stage fibrous anion exchange (AEX) clarification met or exceeded the performance of the conventional two‐stage depth filtration systems in terms of product recovery, removal of process‐related impurities, and throughput. The one‐stage anion clarification approach had a smaller footprint, a shorter set‐up time, an easier setup, consumed less buffer flush volume, and operated at a lower differential pressure relative to those of conventional systems. In a comparability study at 200 L scale, antibodies in cell culture fluid (CCF) clarified by depth filtration system exhibited product quality degradation due to disulfide bond reduction (DSBR), whereas antibodies clarified by AEX fiber method were not. We surmised that the lower operating differential pressure and electrostatic adsorption mechanism of the anion clarification system minimized the potential of product to undergo DSBR. We developed a bench‐scale process model that allowed us to assay DSBR and predict the process results. We then utilized it to demonstrate that the antibody was reduced when clarified with a two‐stage 3 M™ Zeta Plus™ Depth Filter system but not with the anionic clarification system. This bench‐scale DSBR assay allowed us to rank the relative disulfide bond reduction potentials of various monoclonal antibodies (mAbs) and demonstrate the reduction‐mitigating impacts of the fibrous clarification approach on a reduction‐prone antibody culture at 2000 L processing scale.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biologics Pilot Lab, PDM, Gilead Sciences, Foster City, California, USA.
- Biologics Development Isolation & Purification, Bayer Healthcare LLC, Berkeley, California, USA.
- Manufacturing Science and Technology - Purification Lonza, Vacaville, California, USA.
- Pre-Pivotal Purification Development, PDM, Gilead Sciences, Foster City, California, USA.
- Process Development, Ultragenyx Pharmaceutical Inc., South San Francisco, California, USA.
ORCID-Profile: Hendri Tjandra
Zitieren
APA
Tjandra, H., Surendar, D., Yoon, I., Rusly, F., Su, Y., Thai, V., Liu, Y., & Hesslein, A. (2026). Disulfide bond reduction of antibodies during clarification: A bench‐scale assay and a mitigation tool. Biotechnology Progress, 42(4). https://doi.org/10.1002/btpr.88507
Vancouver
Tjandra H, Surendar D, Yoon I, Rusly F, Su Y, Thai V, et al. Disulfide bond reduction of antibodies during clarification: A bench‐scale assay and a mitigation tool. Biotechnology Progress. 2026;42(4). doi:10.1002/btpr.88507
BibTeX
@article{Tjandra2026,
author = {Tjandra, Hendri and Surendar, Deepa and Yoon, Isu and Rusly, Florence and Su, Yan and Thai, Vu and Liu, Yi and Hesslein, Ashley},
title = {Disulfide bond reduction of antibodies during clarification: A bench‐scale assay and a mitigation tool},
journal = {Biotechnology Progress},
year = {2026},
volume = {42},
number = {4},
doi = {10.1002/btpr.88507}
}
EUVIMED